Nature Communications (Apr 2021)
Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling
- Guijie Guo,
- Ming Gao,
- Xiaochen Gao,
- Bibo Zhu,
- Jinzhou Huang,
- Xinyi Tu,
- Wootae Kim,
- Fei Zhao,
- Qin Zhou,
- Shouhai Zhu,
- Zheming Wu,
- Yuanliang Yan,
- Yong Zhang,
- Xiangyu Zeng,
- Qian Zhu,
- Ping Yin,
- Kuntian Luo,
- Jie Sun,
- Min Deng,
- Zhenkun Lou
Affiliations
- Guijie Guo
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Ming Gao
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Xiaochen Gao
- Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science
- Bibo Zhu
- Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science
- Jinzhou Huang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Xinyi Tu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Wootae Kim
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Fei Zhao
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Qin Zhou
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Shouhai Zhu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Zheming Wu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Yuanliang Yan
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Yong Zhang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Xiangyu Zeng
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Qian Zhu
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Ping Yin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Kuntian Luo
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Jie Sun
- Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic College of Medicine and Science
- Min Deng
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- Zhenkun Lou
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
- DOI
- https://doi.org/10.1038/s41467-021-22484-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
The RNA-sensing pathway has been associated with type I interferon (IFN) production induced by DNA damaging agents. Here the authors reveal that RIG-I, a cytosolic RNA sensor that recognizes RNA virus and initiates IFN signaling, is recruited to double-stranded breaks and suppresses non-homologous end joining.
